Dr. Aurora Mirabile

Specialised Oncologist

Thyroid Tumours – Head-Neck Tumours – Oral Cavity Tumours – Larynx Tumours – Pharynx Tumour – Paranasal sinuses Tumour – Salivary Glands Tumour

“Cancer is one of the diseases in which a patient needs even more support from a doctor and in many different ways: the patient is often incapacitated and his or her social life is considerably affected. My objective is to guarantee the best therapeutic approach linked to support therapies, so that a patient can recover and maintain a good quality life."

– Aurora Mirabile –

IRCCS San Raffaele Hospital in Milano (since 2017)

– Oncologist at the Experimental Oncology Division of the San Raffaele Hospital in Milan

Clinical and Research Activity

Doctor Mirabile performs clinical and research activities on Head-Neck Tumours with a focus in the study of new pharmaceutical drugs with a biological and immunotherapeutic effect.

In addition, she is engaged in the study of support therapies that enable personalised management of side effects and cancer related symptoms, while safeguarding the patient’s quality of life as much as possible. She has followed and participated in the development of various innovative treatments such as line II immunotherapy treatments for advanced neck-head tumours.

Other Activities

Creator and Promoter of the website dedicated to head-neck tumours www.tumoritestaecollo.it

Education and training

Medical and Surgical Degree at the Università Statale di Milano-Bicocca (2004)

Specialization in Medical Oncology at Università degli Studi of Milan (2009)

ER pediatric course organised by ABIO (2000-2001)

Italian Red Cross certified Practical and theoretical First Aid Course (1995-1996)

Registered to the Certified Medical Association

Registered to the Certified Medical Association Albo dei Medici in Milan, n° 39408.

Medical Career

Works at the San Raffaele Hospital in Milan as an Oncologist from 2017.

1st Level Medical Manger in Oncology for Azienda Ospedaliera Sant’Antonio Abate Gallarate (VA), ASST Valleolona (2015-2017)

Oncologist at the head-neck division at the Istituto Nazionale dei Tumori in Milan (2009-2014)

Specialising in the head-neck division in Oncology at the Istituto Nazionale dei Tumori in Milan (2009)

Specialising in the hematology-oncology division at Istituto Nazionale dei Tumori in Milan (2006-2009)

In 2006 a 1-year scholarship given to an oncologist for the development of the research project “Adjuvant Therapy in the elderly” at the Istituto Europeo Di Oncologia in Milan

Intern in the Oncology Division at the Istituto Europeo Di Oncologia in Milan (2003-2005)

She has attended the Internal Medicine Division at the San Paolo Hospital in Milan (1997-1998)

Volunteer at the Gaetano Pini Hopsital in Milan (1996-1998)

Scientific Societies

Member of AIOM, Associazione Italiana di Oncologia Medica

Member of ESMO European society for Medical Oncology

Member of AIOCC Associazione Italiana di Oncologia Cervico-Cefalica

Member of EORTC European Organization for Research and Treatment of Cancer

Member of NICSO Network Italiano Cure di Supporto in Oncologia

Languages

Italian – English – French

Treated cancer diseases

Head-Neck Tumours
Immuno-oncology
Larynx Tumours
Oral Cavity Tumours
Paranasal sinuses Tumour
Pharynx Tumour
Salivary Glands Tumour
Thyroid Tumours

San Raffaele Hospital
Oncology Division
Via Olgettina 60
20132 Milan, Italy


Contact

Per prenotare una visita ambulatoriale in libera professione: +39 02 26436560

Per prenotare una visita ambulatoriale tramite SSN: +39 02 26432643


Online medical consultation with Dr. Aurora Mirabile

Hyperspecialization at the service of Neoplasies

Hyperspecialization at the service of Neoplasies

Hyperspecialization at the service of neoplasies. Anatomy of a phenomena Article by Aurora MirabileOncologist specialised in head and neck tumoursSan…

Leggi tutto l'articolo

Author and co-author of 16 scientific publications selected by Pubmed and available on Researchgate.

Has participated to more than 21 educational lectures, presentations at national and international events.

Her articles are published in internationally renowned scientific magazines such as Annal of Oncology, Critical Reviews in Oncology/Hematology, Head and Neck, Future Oncology, Supportive Care in Cancer.

Publications

Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker.
Signorelli D, Giannatempo P, Grazia G, Aiello MM, Bertolini F, Mirabile A, Buti S, Vasile E, Scotti V, Pisapia P, Cona MS, Rolfo C, Malapelle U, Group IY.
Biomed Res Int. 2019 Apr 24;2019:9056417. doi: 10.1155/2019/9056417. eCollection 2019. Review.

PD-1 Inhibitors-Related Neurological Toxicities in Patients with Non-Small-Cell Lung Cancer: A Literature Review.
Mirabile A, Brioschi E, Ducceschi M, Piva S, Lazzari C, Bulotta A, Viganò MG, Petrella G, Gianni L, Gregorc V.
Cancers (Basel). 2019 Mar 1;11(3).

Prognostic factors in recurrent or metastatic squamous cell carcinoma of the head and neck.
Mirabile A, Miceli R, Calderone RG, Locati L, Bossi P, Bergamini C, Granata R, Perrone F, Mariani L, Licitra L.
Head Neck. 2019 Jan 16.

Prevalence, characteristics, and treatment of fatigue in oncological cancer patients in Italy: a cross-sectional study of the Italian Network for Supportive Care in Cancer (NICSO).
Roila F1, Fumi G2, Ruggeri B3, Antonuzzo A4, Ripamonti C5, Fatigoni S2, Cavanna L6, Gori S7, Fabi A8, Marzano N9, Graiff C10, De Sanctis V11, Mirabile A12, Serpentini S13, Bocci C14, Pino MS15, Cilenti G16, Verusio C17, Ballatori E18; NICSO (Network Italiano per le Cure di Supporto in Oncologia).
Support Care Cancer. 2018 Aug 6. doi: 10.1007/s00520-018-4393-9.

Predictors of Patient-Reported Dysphagia Following IMRT Plus Chemotherapy in Oropharyngeal Cancer.
Orlandi E1, Miceli R2, Infante G2, Mirabile A3, Alterio D4, Cossu Rocca M5, et al.
Dysphagia. 2018 Jun 8. doi: 10.1007/s00455-018-9913-8.

Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?
Lazzari C1, Karachaliou N2, Bulotta A3, Viganó M3, Mirabile A3, Brioschi E3, Santarpia M4, Gianni L3, Rosell R5, Gregorc V3
Ther Adv Med Oncol. 2018 Apr 6;10:1758835918762094. doi: 10.1177/1758835918762094. eCollection 2018.

Report from European Association for the Study of the Liver: HCC Summit, Geneva, Switzerland, 2-5 February 2017.
Sacco R, Mirabile A, Giacomelli L, Bresci G, Attardo S, Cabibbo G.
Future Oncol. 2017 Jun; 13(15);1297-1300

A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.
Locati LD, Perrone F, Cortelazzi B, Bergamini C, Bossi P, Civelli E, Morosi C, Lo Vullo S, Imbimbo M, Quattrone P, Dagrada GP, Granata R, Resteghini C, Mirabile A, Alfieri S, Orlandi E, Mariani L, Saibene G, Pilotti S, Licitra L.
Eur J Cancer. 2016 Dec; 69:158-165.

Incidence, characteristics and treatment of fatigue in oncological cancer patients (pts) in Italy: a cross section study.
F. Roila1, F. Spina1, C. Ripamonti2, A. Antonuzzo, L. Cavanna, S. Gori, A. Mirabile, A. Gabi, N. Marzano, C. Graiff, V. De Sanctis, S. Serpentini, C. Bocci, M.S. Pino, G. Cilenti, C. Verusio, S. E. Lutrino, S. Fatigoni, E. Ballatori.
Annals of Oncology, Supplement 4, Vol 27, Oct 2016.

Temporal course and predictive factors of analgesic opioid requirement for chemoradiation-induced oral mucositis in oropharyngeal cancer.
Alfieri S1, Ripamonti CI2, Marceglia S3, Orlandi E4, Iacovelli NA4, Granata R1, Cavallo A5, Pozzi P6, Boffi R6, Bergamini C1, Imbimbo M1, Pala L1, Resteghini C1, Mirabile A1, Locati LD1, Licitra L1, Bossi P1.
Head Neck. 2016 Feb 5

Pain management in head and neck cancer patients undergoing chemo-radiotherapy: Clinical practical recommendations.
Mirabile A1, Airoldi M2, Ripamonti C3, Bolner A4, Murphy B5, Russi E6, Numico G7, Licitra L8, Bossi P9.
Crit Rev Oncol Hematol. 2015 Dec 3.

Healthcare-associated infections in patients with head and neck cancer treated with chemotherapy and/or radiotherapy.
Mirabile A, Vismara C, Crippa F, Bossi P, Locati L, Bergamini C, Granata R, Resteghini C, Conte E, Morelli D, Scarpellini P, Licitra L.
Head Neck. 2015 Jun 3

Sepsis in head and neck cancer patients treated with chemotherapy and radiation: Literature review and consensus.
Mirabile A, Numico G, Russi EG, Bossi P, Crippa F, Bacigalupo A, De Sanctis V, Musso S, Merlotti A, Ghi MG, Merlano MC, Licitra L, Moretto F, Denaro N, Caspiani O, Buglione M, Pergolizzi S, Cascio A, Bernier J, Raber-Durlacher J, Vermorken JB, Murphy B, Ranieri MV, Dellinger RP.
Crit Rev Oncol Hematol. 2015 Mar 19. pii: S1040-8428(15)00050-5.

Italian version of the M.D. Anderson Symptom Inventory-Head and Neck Module: linguistic validation.
Greco A, Orlandi E, Mirabile A, Takanen S, Fallai C, Iacovelli NA, Rimedio A, Russi E, Sala M, Monzani D, Rosenthal DI, Gunn GB, Steca P, Licitra L, Bossi P.
Support Care Cancer. 2015 Mar 21.

Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study.
Roila F, Ruggeri B, Ballatori E, Fatigoni S, Caserta C, Licitra L, Mirabile A, Ionta MT, Massidda B, Cavanna L, Palladino MA, Tocci A, Fava S, Colantonio I, Angelelli L, Ciuffreda L, Fasola G, Zerilli F; Italian Group for Antiemetic Research.
Ann Oncol. 2015 Mar 5.

Aprepitant versus metoclopramide, both combined with dexamethasone, for preventing cisplatin-induced delayed emesis: a randomized, double-blind study.
Roila F, Ballatori E, Ruggeri B, Fatigoni S, Mirabile A, Frau B., Cavanna L, Fava S, Colantonio I, Angelelli L, Lutrino E. S., Zerilli F.
I Supplementi di Tumori Vol 15, n°1, Oct 2014.

Fentanyl pectin nasal spray as treatment for incident predictable breakthrough pain (BTP) in oral mucositis induced by chemoradiotherapy in head and neck cancer.
Bossi P, Locati L, Bergamini C, Mirabile A, Granata R, Imbimbo M, Resteghini C, Licitra L.
Oral Oncol. 2014 Jul 4.

Evaluation of an every-other-day palonosetron schedule to control emesis in multiple-day high-dose chemotherapy.
Mirabile A, Celio L, Magni M, Bonizzoni E, Gianni AM, Di Nicola M.
Future Oncol. 2014 Jun 20:1-10.

Prognostic factors in patients (pts) with recurrent and/or metastatic (RM) head and neck carcinoma (HNC) treated qith cetuximab plus chemotherapy.
Mirabile A., Bossi P., Cossu Rocca M., Ferrari D., Battisti N., Locati LD., Marceglia S., Licitra L.
ECCHNO poster abstract April 2014.

Surveillance of head and neck cancer (hnc) patients: clinical And radiological exams or symptom driven follow-up?
Imbimbo M., Bossi P., Potepan P., Fallai C., Scaramellini G., Locati L., Orlandi E., Bergamini C., Mirabile A., Granata R., Resteghini C., Licitra L.
I Supplementi di Tumori Vol 14, n°1, Oct 2013

Sorafenib in recurrent and/or metastatic salivary gland carcinomas (RMSGCs): An investigator-initiated phase II trial (NCT01703455).
Laura L., Federica Perrone, Barbara Cortelazzi, Dagrada P., Paolo Bossi, Enrico M. Civelli, Cristiana Bergamini, Pasquale Quattrone, Martina Imbimbo, Aurora Mirabile, Roberta Granata, Carlo Resteghini, Camilla Cassani, Alfonso Marchianò, Gabriella Saibene, Silvana Pilotti.
I Supplementi di Tumori Vol 14, n°1, Oct 2013

Health care-associated infections (HAIs) in head and neck carcinoma (HNC) patients treated with chemotherapy (CT) and/or radiotherapy (RT).
Aurora Mirabile, Chiara Vismara, Paolo Bossi, Laura D. Locati, Cristiana Bergamini, Roberta Granata, Carlo Resteghini, Daniele Morelli, Paolo Scarpellini, Lisa F. Licitra
J Clin Oncol 31, 2013 (suppl; abstr 6046)

Sorafenib in recurrent and/or metastatic salivary gland carcinomas (RMSGCs): An investigator-initiated phase II trial (NCT01703455).
Laura D. Locati, Paolo Bossi, Enrico M. Civelli, Federica Perrone, Cristiana Bergamini, Barbara Cortelazzi, Pasquale Quattrone, Martina Imbimbo, Aurora Mirabile, Roberta Granata, Carlo Resteghini, Luigi Mariani, Davide Tosarello, Camilla Cassani, Alfonso Marchiano', Gabriella Saibene, Silvana Pilotti, Lisa F. Licitra
J Clin Oncol 31, 2013 (suppl; abstr 6020)

Identification of a gene expression profile associated with progression-free survival (PFS) in relapsed or metastatic (RM) head and neck squamous cell cancer (HNSCC) patients (pts) treated with first-line cetuximab and platinum therapy.
Paolo Bossi, Loris De Cecco, Federica Perrone, Barbara Cortelazzi, Maria Cossu Rocca, Siano Marco, Andrea Sponghini, Cristiana Bergamini, Laura D. Locati, Aurora Mirabile, Roberta Granata, Carlo Resteghini, Silvana Pilotti, Silvana Canevari, Lisa F. Licitra.
J Clin Oncol 31, 2013 (suppl; abstr 6027).

Healthcare associated infections in head and neck carcinoma patients treated with chemotherapy and/or radiotherapy.
A. Mirabile, C. Vismara, P. Bossi, L. Locati, C. Bergamini, R. Granata, C. Resteghini, D. Morelli, P. Scarpellini, L. Licitra.
Ann Oncol. 2012 Sept, vol 23.

Association between salivary cytokine levels and chemoradiotherapy-induced toxicities in head and neck cancer patients.
Paolo Bossi, Paola Filipazzi, Carlo Resteghini, Rosalba Miceli, Ester Orlandi, Laura Locati, Carlo Fallai, Silvia Tana, Agata Cova, Paola Squarcina, Monica Rodolfo, Cristiana Bergamini, Roberta Granata, Aurora Mirabile, Licia Rivoltini, Lisa F. Licitra.
J Clin Oncol 30, 2012 (suppl; abstr5555)

Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation study.
Granata R, Miceli R, Orlandi E, Perrone F, Cortelazzi B, Franceschini M, Locati LD, Bossi P, Bergamini C, Mirabile A, Mariani L, Olmi P, Scaramellini G, Potepan P, Quattrone P, Ang KK, Licitra L.
Ann Oncol. 2012 Jul;23(7)

Targeted therapy in head and neck cancer
Lisa Licitra, Cristiana Bergamini, Aurora Mirabile and Roberta Granata.
Curr Opin Otolaryngol Head Neck Surg. 2011 Mar 2. 19:132–137

Outcome of Squamous Larynx Cancer (LC) in Patients Aged >70 -a Mono-institutional Case-series Review.
L. Locati, A. Mirabile, P. Bossi, E. Orlandi, G. Scaramellini, S. Riccio, P. Olmi, L. Licitra.
European Journal of Cancer Vol. 47 Supplement 1, September 2011

Docetaxel, cisplatin and 5-fluorouracil-based induction chemotherapy followed by intensity-modulated radiotherapy concurrent with cisplatin in locally advanced EBV-related nasopharyngeal cancer.
Bossi P, Orlandi E, Bergamini C, Locati LD, Granata R, Mirabile A, Parolini D, Franceschini M, Fallai C, Olmi P, Quattrone P, Potepan P, Gloghini A, Miceli R, Mattana F, Scaramellini G, Licitra L.
Ann Oncol. 2011 Mar 11.

Prognostic factors influencing outcome of patients with recurrent or metastatic carcinoma (R&M) of the head and neck: results of an italian monoinstitutional study.
A. Mirabile1, R. Calderone1, R. Miceli2, F. Mattana2, L. Locati1, P. Bossi1, C. Bergamini1, R. Granata1, L. Mariani2, L. Licitra1.
I Supplementi di Tumori Vol 10, n°1, Oct 2010

Survival of patient with oropharyngeal cancer according to HPV status, smoke and tumor presentation: an italian validation study
R. Granata1, F. Perrone2, R. Miceli4, M. Franceschini3, E. Orlandi3 , P. Bossi1, L. Locati1, C. Bergamini1, R. Calderone1, A. Mirabile1, B. Cortelazzi2, S. Pilotti2 , L. Mariani4, P. Olmi3, K.K. Ang5, L. Licitra1
I Supplementi di Tumori Vol 10, n°1, Oct 2010.

Samitalâ in prophylaxis of chemo-radiotherapy (CT-RT) induced mucositis in head and neck squamocellular cancer (HNSCC) patients (PTS): Results of a prospective monoinstitutional phase II trial.
Bergamini C1, Bossi P1, Mirabile A1, Orlandi E2, Franceschini M2, Olmi P2, Granata R1, Locati LD1, Licitra L1.
Annals of Oncology, Supplement 8, Vol 21, Oct 2010.

Comment on “Acute toxicity of three versus two courses of cisplatin for radiochemotherapy of locally advanced squamous cell carcinoma of the head and neck (SCCHN): A matched pair analysis", by Rades et coll.
Bossi P, Granata R, Bergamini C, Mirabile A, Locati L, Licitra L.
Oral Oncol. 2010 Oct 15.

Prognostic factors influencing outcome of patients with recurrent or metastatic carcinoma (R&M) of the head and neck: results of an italian monoinstitutional study.
A. Mirabile1, R. Calderone1, R. Miceli2, F. Mattana2, L. Locati1, P. Bossi1, C. Bergamini1, R. Granata1, L. Mariani2, L. Licitra1.
Annals of Oncology, Supplement 8, Vol 21, Oct 2010.

Radioactive iodine (131I-RAI)-resistant advanved differentiated thyroid cancer (DTC): A natural history of a mono-institutional series.
Locati LD1, Porcu L2, Seregni E3, Bossi P1, Granata R1, Bergamini C1, Mirabile A1,Torri V2, Licitra L1
Annals of Oncology, Supplement 8, Vol 21, Oct 2010.

– La terapia bersaglio molecolare nei tumori squamosi del testa & collo
Lisa Licitra1, Aurora Mirabile1
Relazione Ufficiale SIO 2010

Trattamento del dolore cronico in paziente con carcinoma del cavo-orale operato e chemio- radio trattato.
Picone A., Mirabile A., Locati L.,Bergamini C.,Franceschini M., Granata R., Bossi P., Olmi P., Licitra L.
Wolters Kluwer Health Italy 2010

MALT lymphoma and Kaposi Sarcoma in an HIV-negative patient.
Mirabile A, Devizzi L, Gianni AM, Cabras A, Carbone A.
Am J. Haematol. 2010 Jun 29

Palonosetron plus dexamethasone for the prevention of emesis induced in patients receiving single and multiple-day high-dose chemotherapy.
M. Di Nicola, A. Mirabile, C. Carlo-Stella, A. Necchi, M. Magni, E. Schiavello, A.M. Gianni.
Poster EBMT April 2008

Books

Author and Co-Author of various books in the field of head-neck tumors and support therapy:
La terapia bersaglio molecolare nei tumori squamosi del testa & collo.
Lisa Licitra, Aurora Mirabile.
Relazione ufficiale SIO 2010 – contributo in capitolo.

Trattamento del dolore cronico in paziente con carcinoma del cavo-orale operato e chemio-radio trattato.
Picone A., Mirabile A., Locati L., Bergamini C., Franceschini M., Granata R., Bossi P., Olmi P., Licitra L.
Wolters Kluwer Health Italy 2010- contributo in capitolo.

Emesi nei regimi multy day e nel trattamento chemio-radio. Tumori della testa e del collo.
A cura di Lisa Licitra, Aurora Mirabile, Anna Merlotti.
G.EM.MA. Gestione dell’Emesi nel Malato Oncologico 2016 – contributo in capitolo.

Modelli organizzativo-gestionali di strutture dedicate di cure di supporto al paziente oncologico in Italia.
C. Ripamonti, A. Antonuzzo, A. Mirabile, S. Artale.
Manuale di cure di supporto in oncologia – I edizione 2015 -contributo in capitolo.

Manuale di cure di supporto in oncologia
A. Antonuzzo, P. Bossi. A. Fabi, C. Ripamonti, D. Santini
Società Editrice Universo

Trattamento del BTcP: esperienze cliniche real life.
Springer Healthcare Communication, n. 4 giugno 2019

Head and Neck Cancer. Psychological and Psychosocial Effects.
Fundakowski, Christopher E. (Ed.)

Radio Wellness, 8 marzo 2018

#Salute: La telemedicina

Le moderne tecnologie e le recenti disposizioni normative in materia di telemedicina offrono l'opportunità di ricevere un consulto medico specialistico in pochi giorni, evitando le lunghe liste d'attesa che affliggono la sanità italiana. Ad #Salute abbiamo fatto il punto sulla situazione sanitaria italiana di oggi e abbiamo presentato il servizio offerto da una start-up innovativa. Riascolta la puntata su Radio Wellness.


Medinews, 5 maggio 2015

Sepsi in pazienti con tumore testa-collo trattati con chemio e radioterapia: revisione della letteratura e consenso

La chemio-radioterapia ha ampliato le possibilità di cura nei pazienti con tumore testa-collo localmente avanzato e in quelli con tumore della laringe e dell'ipofaringe ha permesso la preservazione dell'organo e della sua funzione. Sono aumentate, tuttavia, le altre cause di morte (per tossicità acuta e tardiva), che diminuiscono il beneficio di sopravvivenza globale in questi pazienti. La diagnosi di sepsi/infezione durante il trattamento dei pazienti con tumore a testa e collo è rara e il problema è sottostimato. Continua a leggere su Medinews

How to apply for an online medical consultation

Register your details in the secure area and choose the doctor according to your disease.

Fill in the medical history form and upload your reports and clinical exams.

Enter your billing information and make the payment.

Within 5 working days you will receive the doctor's online consultation.